The study and its comparison
A randomized controlled trial enrolled 1,021 participants. Its population was adults with a recent colorectal adenoma. The comparison used folic acid 1 mg daily versus placebo; separate aspirin allocation, with observation over two colonoscopic surveillance intervals. [1]
At the first three-year assessment, adenoma recurrence was 44.1% versus 42.4%, without a significant difference. Among 607 with second surveillance, advanced lesions occurred in 11.6% versus 6.9%, a borderline statistical signal. [1]
What the finding establishes
Reduced participation at later surveillance and secondary comparisons limit certainty about harm. Neither food folate nor a folic-acid and vitamin-D combination was tested. The trial does not justify a general recommendation to avoid folate-containing foods. Funding and complete conflicts were not established from the retrieved abstract. [1]
A hypothetical distinction
Imagine the primary recurrence endpoint is negative and a later advanced-lesion endpoint suggests harm. Both belong in the interpretation.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.